Drug Profile
GSK 2434735
Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antiasthmatics
- Mechanism of Action Interleukin 13 inhibitors; Interleukin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 01 May 2012 GlaxoSmithKline completes a phase I trial in Healthy volunteers in United Kingdom (NCT01563042)
- 03 Apr 2012 Phase-I clinical trials in Asthma in United Kingdom (IV)
- 03 Apr 2012 Phase-I clinical trials in Asthma in United Kingdom (SC)